Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medical Advances Get More Chances When Safety Issues Arise

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Withdrawn “me too” NMEs were removed from the market sooner after post-marketing safety signals than first-in-class or advance-in-class NMEs, showing the importance of available alternative therapy (or the lack thereof) in post-marketing risk management decisions.

Advertisement

Related Content

Safety Events For Accelerated Approval Drugs Highlighted As Expansion Looms
Lower Level Of Innovation Could Undermine Expedited Approval Pathways
Drug Safety Forecast: Greater Understanding Could Signal Fewer Withdrawals
Drug Safety Forecast: Greater Understanding Could Signal Fewer Withdrawals
Can Iclusig Return To Market? Ariad Sees Path Through Restricted Distribution REMS
What Innovation Crisis? First-In-Class Drug Approvals Stable For Almost 25 Years, FDA Says
Will CV Verdicts For Onglyza, Nesina Cause FDA To Change Its Tune On Antidiabetic Safety?
Avandia Review Endorsement Aided By Good Data, Cultural Shift On Safety
FDA “Regulatory Flexibility” On Accelerated Approval Must Result In Some Withdrawals
Pfizer Trovan Suspension Recommended In EU; Distribution Limited In U.S.

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS005281

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel